| 0.2448 0.028 (12.71%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.36 |
1-year : | 0.43 |
| Resists | First : | 0.31 |
Second : | 0.37 |
| Pivot price | 0.26  |
|||
| Supports | First : | 0.2 |
Second : | 0.17 |
| MAs | MA(5) : | 0.23 |
MA(20) : | 0.26 |
| MA(100) : | 0.17 |
MA(250) : | 1.17 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 14.3 |
D(3) : | 9.2 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 5 | Low : | 0.08 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KTRA ] has closed above bottom band by 33.0%. Bollinger Bands are 0.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.25 - 0.25 | 0.25 - 0.25 |
| Low: | 0.21 - 0.21 | 0.21 - 0.21 |
| Close: | 0.24 - 0.25 | 0.25 - 0.25 |
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Tue, 14 May 2024
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results - PR Newswire
Thu, 04 Apr 2024
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA - Yahoo Finance
Wed, 03 Apr 2024
Kintara Therapeutics Announces Strategic Acquisition of TuHURA Biosciences - TipRanks
Wed, 03 Apr 2024
Why Kintara Therapeutics Shares Are Gaining Today - Benzinga
Wed, 03 Apr 2024
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 2,850 (K) |
| Shares Short P.Month | 4,740 (K) |
| EPS | -2.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -83 % |
| Return on Equity (ttm) | -192.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | 0 |
| Price to Book value | -3.07 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|